Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.81 USD | -1.43% | +2.34% | +5.95% |
Apr. 01 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
Mar. 27 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.95% | 438M | |
-2.47% | 88.14B | |
+1.45% | 40.44B | |
-14.43% | 32.24B | |
+51.90% | 24.39B | |
-14.85% | 15.59B | |
-13.87% | 12.14B | |
-7.87% | 12.18B | |
-39.40% | 12.3B | |
+4.87% | 8.87B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Annexon Says Huntington's Disease Drug Stabilized Disease Progression in Phase 2 Trial; Shares Rise